Hikma announces new president of injectables business

The FTSE 250 firm said the new role would take effect from 1 September.

Based in the US, Dr Larkins would be directly reporting to Riad Mishlawi, Hikma's newly-designated chief executive officer.

Hikma said Dr Larkins would bring with him a wealth of expertise in the sterile injectable generic market.

Prior to the new role, he served as the CEO of Custopharm, a company which was integrated into Hikma's portfolio in 2022.

Following the acquisition, Dr Larkins took on the responsibility of Hikma's senior vice-president of injectables research and development.

Dr Larkins had previously been at the helm of a number senior leadership roles at prominent injectable pharmaceutical firms, including stints at Bedford Laboratories and ESI Lederle/Baxter, as well as at Schein Pharmaceuticals' Steris Laboratories in Phoenix and at Amylin Pharmaceuticals.

“Bill's exceptional leadership skills, vast expertise, and successful track record make him the ideal person to lead our injectables team,” said Riad Mishlawi, current president of injectables and CEO-elect.

“Over the next few years, we have a tremendous opportunity to further expand Hikma's position as a market-leading manufacturer and supplier of generic injectable medicines.

“I look forward to working with Bill in his new role.”

At 0910 BST, shares in Hikma Pharmaceuticals were up 0.5% at 2,205p.

Reporting by Josh White for Sharecast.com.